Ocular Surface最新文献

{"title":"Recurrent retroprosthetic membranes in Boston Keratoprosthesis Type I: Incidence, risk factors, and complications","authors":"Katherine G. Chen ,&nbsp;Taylor W. Starnes ,&nbsp;Sasha Kravets ,&nbsp;Shanta Ghosh ,&nbsp;Jose de la Cruz ,&nbsp;Maria S. Cortina","doi":"10.1016/j.jtos.2025.11.002","DOIUrl":"10.1016/j.jtos.2025.11.002","url":null,"abstract":"<div><h3>Purpose</h3><div>To identify pre-operative surgical factors associated with recurrent retroprosthetic membranes (RPMs) after Boston Keratoprosthesis (KPro) implantation, and to compare outcomes of patients with recurrent RPMs to those who had single or no RPM formation.</div></div><div><h3>Methods</h3><div>A single-center, retrospective study of all patients who underwent Boston Type I KPro implantation between 2006 and 2017 was performed. Patients with less than 1 year follow-up after device implantation were excluded. Patients were divided into 3 groups – no RPM, single RPM, and recurrent RPM. Recurrent RPM was defined as ≥2 visually significant RPM during follow-up. Statistical analysis was performed to assess factors associated with RPM status. Primary outcome measures included best-corrected visual acuity at 1 year and the need for RPM-related surgeries.</div></div><div><h3>Results</h3><div>109 of 148 KPro patients met the inclusion criteria. 45 % of patients had no RPM, 36.7 % had a single RPM, and 18.3 % had recurrent RPMs. At 1-year follow-up, visual acuity was decreased in both the recurrent (LogMAR 1.6) and single RPM (LogMar 1.18) groups compared to eyes with no RPM (LogMar 0.94). Eyes with recurrent RPM also required a significantly higher proportion of RPM-related surgery (p &lt; 0.001). Eyes without prior penetrating keratoplasty (p = 0.04), pre-operative aniridia (p = 0.01), and post-operative occurrence of retinal detachments (p &lt; 0.001) and corneal melts (p &lt; 0.001) were found to be statistically significantly associated with RPM status.</div></div><div><h3>Conclusions</h3><div>Retroprosthetic membranes, especially when recurrent, play an important role in the secondary complications, visual outcomes, and device retention after KPro implantation.</div></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":"38 ","pages":"Pages 424-430"},"PeriodicalIF":5.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145509653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in pre-surgical baseline tear proteome are associated with persistent post-refractive surgery pain","authors":"Brooke M. Harkness ,&nbsp;Siting Chen ,&nbsp;Ashok P. Reddy ,&nbsp;Kilsun Kim ,&nbsp;Deborah M. Hegarty ,&nbsp;Steven J. Everist ,&nbsp;Julie A. Saugstad ,&nbsp;Jodi Lapidus ,&nbsp;Anat Galor ,&nbsp;Sue A. Aicher","doi":"10.1016/j.jtos.2025.08.001","DOIUrl":"10.1016/j.jtos.2025.08.001","url":null,"abstract":"<div><h3>Purpose</h3><div>Most patients who undergo refractive surgery have excellent outcomes, but a subset experience persistent eye pain after the procedure. We hypothesized that pre-operative tear fluid proteins are distinct in patients who develop pain after surgery.</div></div><div><h3>Methods</h3><div>Patients undergoing refractive surgery (LASIK or PRK) provided tear fluid samples and eye pain reports (numeric rating scale (NRS) 0–10) before (baseline) and after surgery. Patients reporting no baseline pain, but pain (NRS ≥3) at 3 months (Pain group, n = 31), were compared to patients with no pain before or 3 months after surgery (No Pain group, n = 47). Baseline samples were analyzed by tandem mass tag spectrometry. Proteins demonstrating differential expression based on fold change thresholds, area under the ROC curve (AUC), or feature importance in random forest classification were identified and used to construct multi-protein models.</div></div><div><h3>Results</h3><div>Thirty-nine proteins showed differential expression between Pain and No Pain patients. Multi-protein models showed that a subset of 4 proteins classified the Pain group with an AUC of 0.87 (95 % CI, 0.79–0.96). This model contained 2 proteins that increased (PGRC1 and PFD3) and 2 proteins that decreased (IBP3 and SPB9) in Pain patients, showing bi-directional, dynamic effects.</div></div><div><h3>Conclusion</h3><div>Analysis of pre-surgical tears reveals proteome differences in patients who go on to experience persistent pain 3 months after refractive surgery. Since these tear samples were taken prior to surgery, when patients were not experiencing pain, these protein patterns may inform the discovery of risk biomarkers for persistent post-refractive surgery eye pain.</div></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":"38 ","pages":"Pages 219-229"},"PeriodicalIF":5.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144839577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repurposing schirmer strips for tear biomarker profiling using infrared spectroscopy","authors":"Haozhe Yu,&nbsp;Wenyu Wu,&nbsp;Jinji Cui,&nbsp;Yun Feng","doi":"10.1016/j.jtos.2025.10.004","DOIUrl":"10.1016/j.jtos.2025.10.004","url":null,"abstract":"<div><h3>Aims</h3><div>To develop and validate a label-free analytical platform using attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy on Schirmer strips for tear biomarker profiling, and assess its diagnostic utility in differentiating aqueous-deficient dry eye disease (DED) subtypes.</div></div><div><h3>Methods</h3><div>Tear samples were collected using Schirmer strips from individuals undergoing routine ophthalmic examinations and from patients with aqueous-deficient DED, with or without primary Sjögren's syndrome. The wetted regions of the strips were analyzed using ATR-FTIR spectroscopy. Stepwise linear regression was employed to model the spectral contributions of individual proteins to the simulated tear spectrum. Spectral differences were quantified using Euclidean distances and correlated with biomarker concentrations and clinical parameters using Spearman correlation. Sparse partial least squares discriminant analysis (sPLS-DA) was then applied to classify DED subtypes.</div></div><div><h3>Results</h3><div>Prominent spectral features were observed in the 800-1700 cm⁻¹ and ∼3000 cm⁻¹ regions. Model fit for the simulated tear spectrum progressively improved with the sequential addition of protein spectra. Spectral Euclidean distance effectively captured the biomarker concentration gradient, as exemplified by lactoferrin. It demonstrated stronger correlations with tear film breakup time and lipid layer thickness than Schirmer wetting length and remained stable after elution. sPLS-DA accurately classified DED subtypes with an AUC of 0.963, driven primarily by protein-related spectral features.</div></div><div><h3>Conclusions</h3><div>The integrated tear analysis platform based on ATR-FTIR spectroscopy of Schirmer strips enables accurate, cost-effective differentiation of DED subtypes by capturing tear molecular fingerprints, laying the foundation for integrating tear-based precision medicine into routine clinical workflows.</div></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":"38 ","pages":"Pages 330-336"},"PeriodicalIF":5.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145310447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical duloxetine for treatment of corneal keratinization in Aniridia-Associated Keratopathy","authors":"Marcel Y. Avila ,&nbsp;Mario A. Jimenez-Mora ,&nbsp;Edgar M. Espana","doi":"10.1016/j.jtos.2025.05.011","DOIUrl":"10.1016/j.jtos.2025.05.011","url":null,"abstract":"","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":"38 ","pages":"Pages 41-42"},"PeriodicalIF":5.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144210614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interdisciplinary management of belantamab mafodotin-associated ocular toxicity in clinical practice","authors":"Mattan Arazi ,&nbsp;Aya Wattad ,&nbsp;Hila Magen ,&nbsp;Abraham Avigdor ,&nbsp;Nirit Agay ,&nbsp;Yoav Berger ,&nbsp;Irina S. Barequet","doi":"10.1016/j.jtos.2025.09.003","DOIUrl":"10.1016/j.jtos.2025.09.003","url":null,"abstract":"<div><h3>Purpose</h3><div>Belantamab mafodotin (BLENREP), an antibody–drug conjugate for relapsed/refractory multiple myeloma (RRMM), is associated with corneal toxicity driven by limbal stem cell dysfunction and corneal epithelial damage. We examined how keratopathy severity relates to hematologic management decisions in clinical practice.</div></div><div><h3>Methods</h3><div>Retrospective cohort at a tertiary referral center, including RRMM patients treated with belantamab mafodotin (2019–2022). Ophthalmic examinations were performed at baseline and before each cycle; keratopathy was graded using the Keratopathy and Visual Acuity (KVA) scale. The primary outcome was the association between KVA severity (modeled as a time-dependent covariate) and management (dose reduction, treatment holiday, or discontinuation). Secondary outcomes included predictors of severe KVA, impact of management on immediate KVA change, and timing of the first management change.</div></div><div><h3>Results</h3><div>Among 41 patients (mean age 67.10 ± 11.78 years; 23/41 [56.1 %] female), 38/41 (92.68 %) developed KVA keratopathy. The median time to first KVA occurrence was 4.14 weeks, and to first management change was 7.29 weeks. Higher KVA grade was associated with earlier management change (HR 1.514; 95 % CI 1.048–2.187; p = 0.0270). At the first assessment after the initial intervention, KVA worsened after treatment holidays (+0.70 ± 0.114 grades) and improved after dose reductions (−0.20 ± 0.084; p = 0.0165). Overall, during follow-up, the most common intervention was a treatment holiday (23/37, 56.1 %), followed by dose reduction (16/37, 39.0 %) and discontinuation (6/37, 16.2 %).</div></div><div><h3>Conclusion</h3><div>KVA keratopathy occurred more frequently than in clinical trials, and nearly all patients required treatment modification. Given the strong relationship between KVA severity and management decisions, close ophthalmic monitoring from Grade 1 is warranted to mitigate progression and reduce vision-related morbidity.</div></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":"38 ","pages":"Pages 324-329"},"PeriodicalIF":5.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145226465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AZR-MD-001 0.5% selenium sulfide ophthalmic ointment for the treatment of contact lens discomfort: A vehicle-controlled, randomized, clinical trial","authors":"Fiona Stapleton ,&nbsp;Mark Hinds ,&nbsp;Jacqueline Tan ,&nbsp;Lyndon Jones ,&nbsp;Robin Chalmers ,&nbsp;Charles Bosworth ,&nbsp;Yair Alster","doi":"10.1016/j.jtos.2024.12.009","DOIUrl":"10.1016/j.jtos.2024.12.009","url":null,"abstract":"<div><h3>Background</h3><div>Contact lens discomfort (CLD) is a common problem for CL wearers, and patients with CLD often have changes in meibomian gland function and structure. In a Phase 2 trial AZR-MD-001 0.5% (AZR) ophthalmic ointment improved meibomian gland dysfunction (MGD) in non-lens wearers. The current study evaluated the efficacy and safety of AZR in participants with CLD and concomitant MGD.</div></div><div><h3>Methods</h3><div>Adults with CLD (Contact Lens Dry Eye Questionnaire-8 &gt;12, range 0–37) and MGD (Meibomian Gland Secretion Score [MGS] ≤12, range 0–45) were randomized (1:1) to AZR:vehicle applied twice-weekly in a three-month multicenter, prospective, double-masked study. Endpoints included difference in change from baseline (CFB) in the number of Meibomian Glands Yielding Liquid Secretion (MGYLS), MGS, the ability to wear their lenses as long as desired, and safety.</div></div><div><h3>Results</h3><div>At Month 3, AZR (n = 34) significantly increased the MGYLS and MGS versus vehicle (n = 33), with least squares mean difference (LSMD) CFB in MGYLS of 5.0 (SE = 0.47) for AZR and 1.6 (0.45) for vehicle, <em>P</em> &lt; 0.0001; MGS of 13.8 (SE = 0.67) for AZR and 3.8 (SE = 0.68) for vehicle, <em>P</em> &lt; 0.0001. Significantly more participants treated with AZR were able to wear lenses as long as desired (43% vs. 6%, <em>P</em> = 0.0023). The most common treatment-emergent adverse event (TEAE) was eye irritation (61.8% AZR; 0% vehicle). All TEAEs related to treatment were mild/moderate, transient, and did not result in discontinuation.</div></div><div><h3>Conclusion</h3><div>AZR-MD-001 0.5% significantly improved MGD signs and hours of comfortable CL wear, demonstrating good efficacy, safety, and tolerability in those with CLD.</div></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":"38 ","pages":"Pages 431-439"},"PeriodicalIF":5.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142908138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Significant errors in the paper by Ballesteros-Sánchez A, Rocha-de-Lossada C and Sánchez-González J. Efficacy of eyelid warming devices as first-step treatment in meibomian gland dysfunction: A systematic review with meta-analysis. 2025; 37:33–46","authors":"Jacqueline Tan","doi":"10.1016/j.jtos.2025.04.003","DOIUrl":"10.1016/j.jtos.2025.04.003","url":null,"abstract":"","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":"38 ","pages":"Pages 443-444"},"PeriodicalIF":5.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143880533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptional landscape of aniridia-associated keratopathy through single-cell RNA sequencing","authors":"Masahito Yoshihara ,&nbsp;Rei Kamuro ,&nbsp;Susumu Hara ,&nbsp;Nozomi Nishida ,&nbsp;Koji Ohmoto ,&nbsp;Yuzuru Sasamoto ,&nbsp;Satoshi Kawasaki ,&nbsp;Yoshinori Oie ,&nbsp;Kohji Nishida","doi":"10.1016/j.jtos.2025.05.008","DOIUrl":"10.1016/j.jtos.2025.05.008","url":null,"abstract":"<div><h3>Purpose</h3><div>Aniridia-associated keratopathy (AAK) is a progressive condition characterized by conjunctivalization of the cornea, yet its molecular mechanisms remain largely unknown. This study aims to elucidate the transcriptional landscape of AAK by characterizing the gene expression profiles of corneal epithelial cells in a patient with congenital aniridia.</div></div><div><h3>Methods</h3><div>Single-cell RNA sequencing (scRNA-seq) was performed on epithelial tissues collected from the clear central corneal region and limbus of a 48-year-old female patient with congenital aniridia. The transcriptomic profiles were compared with those of healthy control samples.</div></div><div><h3>Results</h3><div>scRNA-seq analysis revealed that a subpopulation of cells from the clear central corneal region expressed the cornea-specific keratins <em>KRT3</em> and <em>KRT12</em> despite a significant reduction in <em>PAX6</em> expression. These cells exhibited corneal, conjunctival, or mixed gene signatures. Genes associated with wound healing and apoptosis were upregulated in the cornea-like cells from the aniridic cornea, indicating a chronic wound healing state. Elevated <em>KLF4</em> expression and regulon activity were observed in these cornea-like cells. Most limbal epithelial cells exhibited conjunctiva-like characteristics, reflecting a loss of limbal cell identity.</div></div><div><h3>Conclusion</h3><div>While acknowledging the limitations of a single case study, this study provides deeper insights into the transcriptional signatures associated with AAK using scRNA-seq. We identified transcriptional alterations reflecting AAK progression and highlighted potential transcription factors that may contribute to corneal identity maintenance despite PAX6 deficiency. These findings enhance our understanding of AAK and suggest potential therapeutic strategies to slow its progression.</div></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":"38 ","pages":"Pages 43-52"},"PeriodicalIF":5.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144231411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A pilot randomized controlled trial of topical androgen treatment in dry eye","authors":"Jay Ruzhang Jiang ,&nbsp;Rima Khankan ,&nbsp;William H. Ridder III ,&nbsp;Andrew Loc Nguyen ,&nbsp;Jerry R. Paugh","doi":"10.1016/j.jtos.2025.06.002","DOIUrl":"10.1016/j.jtos.2025.06.002","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the safety and efficacy of eyelid androgen gel application to treat moderate to severe dry eye disease.</div></div><div><h3>Methods</h3><div>Twenty four eyes of 24 subjects (12 eyes per arm) were randomized to either eyelid testosterone or vehicle gel. Subjects received either 17β-Hydroxyandrost-4-en-3-one) 4.5 % wt./wt. or vehicle gel, applied twice daily 12 h apart for 4 weeks. Outcome parameters were monitored at 2-, and 4-weeks during dosing, and at 4-, and 8-weeks following dosing cessation.</div></div><div><h3>Results</h3><div>Significant positive differences were found in the androgen arm only, for Schein symptom score, tear meniscus height (TMH), fluorescein tear breakup time (fTBUT) and meibum score (repeated ANOVA, all p = 0.046 or less for each arm comparison) at all follow-up visits compared to baseline. For example, fTBUT in the androgen arm at 4 weeks was 6.2 ± 1.5 s compared to baseline, 3.3 ± 0.9 secs p&lt; 0.001 (Dunnett's test, 95 % CI [1.838, 3.829]). No change was observed for either arm for staining, tear osmolarity, OSDI, non-invasive breakup time (NIBUT), serum lipid levels or hematocrit. Serum testosterone increased ∼ 9-fold in females (paired <em>t</em>-test; p = 0.006; CI [-240.2, −55.6]) in the androgen arm, but not males (paired <em>t</em>-test; p = 0.727; CI [-25.9, 31.2]).</div></div><div><h3>Conclusions</h3><div>Eyelid androgen gel application, 4.5 % wt./wt., was effective in improving tear fTBUT, symptoms, TMH and meibomian secretion grade in dry eye patients. Future research requires a larger sample size, outcome measure variability reduction and formulation optimization for absorption, androgen type, and dosing regimen.</div></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":"38 ","pages":"Pages 56-63"},"PeriodicalIF":5.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric vs adult Stevens Johnson syndrome/toxic epidermal necrolysis: Ocular outcomes and the role of amniotic membrane","authors":"","doi":"10.1016/j.jtos.2025.10.008","DOIUrl":"10.1016/j.jtos.2025.10.008","url":null,"abstract":"","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":"38 ","pages":"Pages 388-389"},"PeriodicalIF":5.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145412015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}